{"id":"NCT02610868","sponsor":"Supernus Pharmaceuticals, Inc.","briefTitle":"Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults","officialTitle":"A Phase 3, Long-Term, Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10","primaryCompletion":"2017-06","completion":"2017-06","firstPosted":"2015-11-20","resultsPosted":"2019-11-04","lastUpdate":"2021-07-13"},"enrollment":187,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Sialorrhea"],"interventions":[{"type":"DRUG","name":"MYOBLOC","otherNames":["rimabotulinumtoxinB","botulinum toxin type B"]}],"arms":[{"label":"MYOBLOC Injection","type":"EXPERIMENTAL"}],"summary":"Multicenter, open-label, outpatient study of the safety and effectiveness of repeated doses of MYOBLOC over a 1-year duration in adult subjects with troublesome sialorrhea.","primaryOutcome":{"measure":"Occurrence, Seriousness, Severity, and Causality Assessment of Treatment Emergent Adverse Events (TEAE)","timeFrame":"Visits at Weeks 4 and 13 combined for each TS; including Visit at Week 8 for TS1","effectByArm":[{"arm":"Treatment Session 1","deltaMin":7,"sd":null},{"arm":"Treatment Session 2","deltaMin":14,"sd":null},{"arm":"Treatment Session 3","deltaMin":3,"sd":null},{"arm":"Treatment Session 4","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":14},"locations":{"siteCount":35,"countries":["United States","Belarus","Ukraine"]},"refs":{"pmids":["40498248"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":187},"commonTop":["Dry mouth","Dental caries","Amyotrophic lateral sclerosis"]}}